MAP2K7 and non-small cell lung carcinoma: MEK inhibitors are considered important candidates for treating KRAS-mutant NSCLC.17–19 This is attributed to their ability to block the KRAS downstream MEK-ERK signal,20 thus limiting the activation of KRAS signaling and impeding tumor development.